ImmunOs Therapeutics has developed a proprietary platform to generate a novel class of human-derived biologic therapeutics capable of stimulating the innate immune system, thereby leading to an activation of both the innate and the adaptive immune system against cancer and infectious diseases. This is a key advantage over currently available immunotherapeutics, which only focus on the modulation of the adaptive immune system.
ImmunOs’ platform differentiates by targeting more cells in the tumor than any competing innate immunity technologies with only one single molecule, thereby changing the immune-suppressing tumor microenvironment.
The Company´s technology platform provides carefully screened HLA variants from patients with autoimmune diseases such as ankylosing spondylitis, Crohn’s Disease or psoriasis in order to identify and develop the most promising molecules for the treatment of tumors and other immune diseases. As ImmunOs Therapeutics´ agents are derived from humans, they show a significantly enhanced safety profile.